While early-stage, the Adagene deal is another example of Sanofi's determination to bolster its R&D pipeline via a string of deals, including a $5.2 billion, strategic-level alliance with UK ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Gain insights into Recursion Pharmaceuticals' Q4 2024 earnings call. Discover clinical advancements, key partnerships, and strategic plans for 2025.

The biopharma industry now has the most extensive and varied clinical pipeline to date, due to decades of groundbreaking ... the scale of the company's drug contributions to the industry. Sanofi ...

Markets are tanking on tariff fears, inflationary concerns and now fears of recession. “Given this is so uncertain and that ...

Key players in the sinusitis drug pipeline market include Bayer, Sanofi, and Pfizer, among others. These companies are at the forefront of developing cutting-edge therapies to improve patient ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

Sanofi invests in Enveda, reaffirming the industry’s confidence in its AI drug discovery platform and ability to deliver differentiated medicines.

Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025KT-621 Phase 1b trial in atopic dermatitis ...